Published in Clin Invest Med on February 01, 1993
Osteoporosis - a current view of pharmacological prevention and treatment. Drug Des Devel Ther (2013) 1.29
Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos Int (2004) 1.01
Significance of Bio-intact PTH(1-84) assay in hemodialysis patients. Osteoporos Int (2004) 0.82
Risk of new vertebral fracture in the year following a fracture. JAMA (2001) 6.17
Canadian normative data for the SF-36 health survey. Canadian Multicentre Osteoporosis Study Research Group. CMAJ (2000) 3.77
Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab (2009) 2.69
Estimation of the prevalence of low bone density in Canadian women and men using a population-specific DXA reference standard: the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporos Int (2000) 2.40
The influence of osteoporotic fractures on health-related quality of life in community-dwelling men and women across Canada. Osteoporos Int (2001) 2.32
Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab (2000) 2.00
Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int (1999) 1.98
Prevalence of IgA-antiendomysial antibody in asymptomatic low bone mineral density. Am J Gastroenterol (2001) 1.54
The osteoporosis care gap in men with fragility fractures: the Canadian Multicentre Osteoporosis Study. Osteoporos Int (2007) 1.48
The association between osteoporotic fractures and health-related quality of life as measured by the Health Utilities Index in the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporos Int (2003) 1.47
Critical impact of patient knowledge and bone density testing on starting osteoporosis treatment after fragility fracture: secondary analyses from two controlled trials. Osteoporos Int (2014) 1.45
25-Hydroxyvitamin D in Canadian adults: biological, environmental, and behavioral correlates. Osteoporos Int (2010) 1.34
Construction and validation of a simplified fracture risk assessment tool for Canadian women and men: results from the CaMos and Manitoba cohorts. Osteoporos Int (2010) 1.27
Construction of a FRAX® model for the assessment of fracture probability in Canada and implications for treatment. Osteoporos Int (2010) 1.25
Fracture prediction and calibration of a Canadian FRAX® tool: a population-based report from CaMos. Osteoporos Int (2010) 1.24
Changes in trabecular and cortical bone microarchitecture at peripheral sites associated with 18 months of teriparatide therapy in postmenopausal women with osteoporosis. Osteoporos Int (2010) 1.24
Oral bisphosphonates are associated with reduced mortality after hip fracture. Osteoporos Int (2010) 1.17
Accuracy of height loss during prospective monitoring for detection of incident vertebral fractures. Osteoporos Int (2004) 1.15
Differences in ankle joint complex range of motion as a function of age. Foot Ankle (1993) 1.14
Persistence, reproducibility, and cost-effectiveness of an intervention to improve the quality of osteoporosis care after a fracture of the wrist: results of a controlled trial. Osteoporos Int (2006) 1.12
Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density. Bone (2010) 1.07
Women with previous fragility fractures can be classified based on bone microarchitecture and finite element analysis measured with HR-pQCT. Osteoporos Int (2012) 1.03
Management of corticosteroid-induced osteoporosis. Semin Arthritis Rheum (2000) 1.01
Autosomal dominant hypoparathyroidism with intracranial calcification outside the basal ganglia. Am J Med Genet (1989) 0.98
Direct release of parathyroid hormone fragments from functioning bovine parathyroid glands in vitro. J Clin Invest (1978) 0.96
Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis. Curr Med Res Opin (2004) 0.95
Nurse case-manager vs multifaceted intervention to improve quality of osteoporosis care after wrist fracture: randomized controlled pilot study. Osteoporos Int (2010) 0.94
Mechanical loading regime and its relationship to bone mineral density in children. Med Sci Sports Exerc (1993) 0.94
Fragility fractures and the osteoporosis care gap in women: the Canadian Multicentre Osteoporosis Study. Osteoporos Int (2010) 0.93
In vitro perifusion for the study of parathyroid hormone secretion: effects of extracellular calcium concentration and beta-adrenergic regulation on bovine parathyroid hormone secretion in vitro. Calcif Tissue Int (1980) 0.90
Short- and long-term outcome of total parathyroidectomy with immediate autografting versus subtotal parathyroidectomy in patients with end-stage renal disease. Am J Nephrol (1999) 0.89
Changing osteocalcin concentrations during pregnancy and lactation: implications for maternal mineral metabolism. J Clin Endocrinol Metab (1987) 0.87
Antiresorptive therapy conserves some periarticular bone and ligament mechanical properties after anterior cruciate ligament disruption in the rabbit knee. J Orthop Res (2004) 0.83
Retracted Nitrate use and changes in bone mineral density: the Canadian Multicentre Osteoporosis Study. Osteoporos Int (2008) 0.83
Cost-effectiveness of a multifaceted intervention to improve quality of osteoporosis care after wrist fracture. Osteoporos Int (2010) 0.83
The association between iliocostal distance and the number of vertebral and non-vertebral fractures in women and men registered in the Canadian Database For Osteoporosis and Osteopenia (CANDOO). BMC Musculoskelet Disord (2002) 0.82
Health-related quality of life measurements in elderly Canadians with osteoporosis compared to other chronic medical conditions: a population-based study from the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporos Int (2005) 0.82
Familial benign hypercalcaemia: hypercalciuria and hypocalciuria in affected members of a small kindred. Clin Endocrinol (Oxf) (1990) 0.82
Secretion of parathyroid hormone by abnormal human parathyroid glands in vitro. J Clin Endocrinol Metab (1977) 0.81
Prevalence of and factors associated with glucosamine use in Canada. Osteoarthritis Cartilage (2006) 0.81
Predicting subsequent bone density response to intermittent cyclical therapy with etidronate from initial density response in patients with osteoporosis. Osteoporos Int (2000) 0.81
Effectiveness of alendronate and etidronate in the treatment of osteoporosis in men: a prospective observational study. Osteoporos Int (2005) 0.81
The calciotropic hormone response to changes in serum calcium during exercise in female long distance runners. J Clin Endocrinol Metab (1993) 0.81
Hypoparathyroidism and pseudotumor cerebri: an infrequent clinical association. Can J Neurol Sci (1987) 0.80
Could a policy of provision of hip protectors to elderly nursing home residents result in cost savings in acute hip fracture care? The case of Ontario, Canada. Osteoporos Int (2007) 0.80
Characteristics of hyperparathyroid states in the Canadian multicentre osteoporosis study (CaMos) and relationship to skeletal markers. Clin Endocrinol (Oxf) (2014) 0.80
Adrenal metastases of renal-cell carcinoma 19 years after nephrectomy. Fine needle aspiration cytology of a case. Acta Cytol (1987) 0.80
Bone mineral density during puberty in western Canadian children. Bone Miner (1992) 0.80
Secondary hyperparathyroidism in chronic renal failure. Pathophysiology and treatment. Med Clin North Am (1978) 0.79
Improved adherence with PTH(1-84) in an extension trial for 24 months results in enhanced BMD gains in the treatment of postmenopausal women with osteoporosis. Osteoporos Int (2012) 0.78
The relationship between serum 25(OH)D and bone density and microarchitecture as measured by HR-pQCT. Osteoporos Int (2015) 0.78
Longitudinal changes in calcium and vitamin D intakes and relationship to bone mineral density in a prospective population-based study: the Canadian Multicentre Osteoporosis Study (CaMos). J Musculoskelet Neuronal Interact (2013) 0.78
Associations of Protein Intake and Protein Source with Bone Mineral Density and Fracture Risk: A Population-Based Cohort Study. J Nutr Health Aging (2015) 0.78
Effects of magnesium ion on parathyroid hormone secretion in vitro. Calcif Tissue Int (1980) 0.77
Bromocriptine reduction of prolactinoma size. Fertil Steril (1981) 0.77
Bone quality in osteopenic postmenopausal women is not improved after 12 months of whole-body vibration training. Osteoporos Int (2015) 0.77
Parathyroid hormone stimulates adenylate cyclase in rat cerebral microvessels. Life Sci (1983) 0.77
Bisphosphonates reduce bone mineral loss at ligament entheses after joint injury. Osteoarthritis Cartilage (2005) 0.77
Activation and inhibition of protein kinase C in cultured bovine parathyroid cells: effect on the release of C-terminal fragments of parathyroid hormone. J Bone Miner Res (1992) 0.77
Positive effect of etidronate therapy is maintained after drug is terminated in patients using corticosteroids. J Clin Densitom (2001) 0.77
The effects of phorbol myristate acetate on the intracellular degradation of bovine parathyroid hormone. Endocrinology (1991) 0.77
Rapid onset of emphysema associated with diffuse parenchymal disease. Am J Med (1979) 0.75
Resectable bronchogenic carcinoma presenting with hypercalcemia: tumor-associated granulomatous reaction and probable production of 1,25-dihydroxyvitamin D. Clin Invest Med (1989) 0.75
Immunohistochemical identification of calcitonin gene-related peptide and substance P in nerves of the bovine parathyroid gland. Cell Tissue Res (1990) 0.75
Parathyroid disorders--pathophysiology, diagnosis and treatment. Minn Med (1980) 0.75
Adaptation, intertrial interval, and response to preferred and non-preferred change. Can J Psychol (1968) 0.75
Dopamine-stimulated parathyroid hormone release in vitro: further evidence for a two-pool model of parathyroid hormone secretion. Can J Physiol Pharmacol (1985) 0.75
A "carboxyl terminal" clinical radioimmunoassay for parathyroid hormone with apparent recognition preference for the intact hormone. J Immunoassay (1985) 0.75
Identification of classical, novel, and atypical protein kinase C isoenzymes in the bovine parathyroid. Endocrinology (1996) 0.75
Strychnine facilitation of latent learning. Psychol Rep (1967) 0.75
Parathyroid hormone and age. N Engl J Med (1979) 0.75
Analysis of parathyroid hormone in bovine parathyroid cysts. J Bone Miner Res (1989) 0.75
Full-term pregnancy after allogeneic transplantation for leukemia in a patient with oligomenorrhea. Bone Marrow Transplant (1989) 0.75
Calcium-dependent release of carboxyl-terminal fragments of parathyroid hormone by hyperplastic human parathyroid tissue in vitro. J Clin Endocrinol Metab (1986) 0.75
Calcium-activated proteases in the bovine parathyroid gland: potential role in degradation of parathyroid hormone to peptide fragments. J Mol Endocrinol (1995) 0.75